Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer-Ingelheim’s Spiriva), LABA/LAMA/ICS FDCs (e.g., GSK’s Trelegy, Chiesi’s Trimbow), and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair / Cinqaero, Sanofi / Regeneron’s Dupixent, GSK’s Nucala) in the market, there is still an unmet need for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use to achieve relief. This Unmet Need report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 31 U.S. pulmonologists, 30 U.S. allergists, and 31 European pulmonologists fielded in March 2021
Key companies: Roche, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, Boehringer-Ingelheim, Sanofi, Regeneron
Key drugs: Xolair, Nucala, Fasenra, Dupixent, Spiriva (tiotropium), LABA/ICS FDCs, LABA/LAMA/ICS FDCs